Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 2:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 5,060 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Capsule 2 Clear all
Completed Phase 1 Interventional

Effect of Clonidine on Responses to Imagery Scripts

NCT00318760
View directory record Official record
Conditions
Cocaine Abuse, Heroin Abuse
Interventions
Clonidine, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Nov 10, 2026, 2:03 PM EST
Completed Phase 2 Interventional Results available

OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic Fibrosis

NCT04375878
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Interventions
MS1819, Porcine PERT
Drug
Lead sponsor
Entero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Long Beach, California • Altamonte Springs, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Nov 10, 2026, 2:03 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules.

NCT04390776
View directory record Official record
Conditions
Healthy Participants
Interventions
PF-06651600
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Hollywood, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Nov 10, 2026, 2:03 PM EST
Completed Phase 2 Interventional

Safety and Efficacy of POMx Capsules in Men With Recurrent Prostate Cancer: An 18-Month Study

NCT01220817
View directory record Official record
Conditions
Recurrent Prostate Cancer
Interventions
3 POMx capsules, 1 POMx capsule
Drug
Lead sponsor
POM Wonderful LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2012 · Synced Nov 10, 2026, 2:03 PM EST
Completed Phase 3 Interventional Results available

A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

NCT05872620
View directory record Official record
Conditions
Obesity, Overweight, Type 2 Diabetes
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
37
States / cities
Pelham, Alabama • Tucson, Arizona • Yuma, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 10, 2026, 2:03 PM EST
Enrolling by invitation Phase 3 Interventional

ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection

NCT04326426
View directory record Official record
Conditions
Coronavirus Infection
Interventions
Tradipitant, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Nov 10, 2026, 2:03 PM EST
Completed Phase 1 Interventional

Evaluate the Effect of Elimune Capsules

NCT02251678
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Elimune Capsules
Dietary Supplement
Lead sponsor
Elorac, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Chicago, Illinois • Lake Forest, Illinois • Fair Lawn, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Nov 10, 2026, 2:03 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

The Influence of Oral Probiotics on the Microbiome and Lipidome

NCT03605108
View directory record Official record
Conditions
Gut Microbiome, Skin Microbiome, Gut Lipidome, Skin Lipidome, Blood Lipidome
Interventions
Probiotic, Placebo
Dietary Supplement · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Nov 10, 2026, 2:03 PM EST
Completed Phase 3 Interventional Results available

Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain

NCT01280591
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111), Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111), Naproxen sodium 440 mg (BAYH6689), DPH 50 mg
Drug
Lead sponsor
Bayer
Industry
Eligibility
12 Years to 45 Years
Enrollment
712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Austin, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Nov 10, 2026, 2:03 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Nutritional Supplement Capsule Containing Curcumin, Green Tea Extract, Polygonum Cuspidatum Extract, and Soybean Extract in Healthy Participants

NCT00768118
View directory record Official record
Conditions
Healthy, no Evidence of Disease
Interventions
curcumin/green tea extract/Polygonum cuspidatum extract/soybean extract capsule, electrophoretic mobility shift assay, laboratory biomarker analysis
Dietary Supplement · Genetic · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2014 · Synced Nov 10, 2026, 2:03 PM EST
Completed Not applicable Interventional

Probiotics in Primary Care

NCT01254097
View directory record Official record
Conditions
Antibiotic Side Effect
Interventions
Probiotic
Dietary Supplement
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 79 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2015 · Synced Nov 10, 2026, 2:03 PM EST
Completed Phase 3 Interventional

The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

NCT00065325
View directory record Official record
Conditions
Locally Advanced Breast Cancer, Metastatic Breast Cancer
Interventions
Fulvestrant, Exemestane
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
32 Years to 91 Years · Female only
Enrollment
694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
51
States / cities
Birmingham, Alabama • Arcadia, California • Fountain Valley, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2015 · Synced Nov 10, 2026, 2:03 PM EST
Terminated Phase 1 Interventional

A Study of Lu AG06466 in Participants With Treatment Resistant Focal Epilepsy

NCT05081518
View directory record Official record
Conditions
Focal Epilepsy
Interventions
Lu AG06466, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Nov 10, 2026, 2:03 PM EST
Completed Phase 2 Interventional

Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)

NCT01279590
View directory record Official record
Conditions
Myalgia, Hypercholesterolemia, Hyperlipidemia
Interventions
PPD10558, Atorvastatin, Placebo
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
40 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
67
States / cities
Anniston, Alabama • Phoenix, Arizona • Huntington Park, California + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2011 · Synced Nov 10, 2026, 2:03 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Microbial Enzyme Impact on Postprandial Nutrient Levels and Gastrointestinal Symptoms in Healthy Adults

NCT05211440
View directory record Official record
Conditions
Digestive Health, Gastrointestinal Health
Interventions
Placebo + Meal, BC-006 + Meal
Dietary Supplement
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
40 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Nov 10, 2026, 2:03 PM EST
Completed Phase 3 Interventional Results available

A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

NCT01376297
View directory record Official record
Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
Netupitant and Palonosetron, Aprepitant, Palonosetron, Dexamethasone
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
11
States / cities
Muscle Shoals, Alabama • Burbank, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2014 · Synced Nov 10, 2026, 2:03 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C

NCT00890318
View directory record Official record
Conditions
HCV Infection
Interventions
ABT-072, ketoconazole, Placebo
Drug · Other
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Waukegan, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 21, 2010 · Synced Nov 10, 2026, 2:03 PM EST
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in U.S. Healthy Participants

NCT07618715
View directory record Official record
Conditions
Healthy Male and Female Subjects
Interventions
Y-4 tablet, Pregabalin capsule, Riluzole tablet
Drug
Lead sponsor
Neurodawn Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Nov 10, 2026, 2:03 PM EST
Completed Phase 1 Interventional

An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor

NCT01231568
View directory record Official record
Conditions
Cancer
Interventions
Regimen A, Regimen B, Regimen C, Regimen D
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Scottsdale, Arizona • Detroit, Michigan • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Nov 10, 2026, 2:03 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg to Verelan® PM Extended-Release Capsules 300 mg

NCT00648050
View directory record Official record
Conditions
Healthy
Interventions
Verapamil Hydrochloride Extended-Release Capsules, 300 mg, Verelan® PM Extended-Release Capsules, 300 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Nov 10, 2026, 2:03 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers

Lactation Fortification Study

NCT01747668
View directory record Official record
Conditions
Lactation
Interventions
Similac Prenatal Vitamin soft-gel capsule, Placebo (soybean oil and dl-alpha-tocopheryl acetate)
Dietary Supplement
Lead sponsor
Abbott Nutrition
Industry
Eligibility
18 Years and older · Female only
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
6
States / cities
Indianapolis, Indiana • Dayton, Ohio • Kettering, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated May 31, 2013 · Synced Nov 10, 2026, 2:03 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Clonidine for Relapse Prevention in Buprenorphine-Maintenance Patients

NCT00295308
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Clonidine, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Nov 10, 2026, 2:03 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Assess the Effect of a Postbiotic on Oxidative Stress and Exercise Performance

NCT06795425
View directory record Official record
Conditions
Oxidative Stress, Healthy, Exercise-induced Muscle Damage, Exercise-induced Muscle Soreness, Immune Function, Gut Health, Microbiome Analysis, Exercise Performance, Exercise Metabolism
Interventions
Postbiotic Active Lifestyle Blend, Placebo
Dietary Supplement · Other
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 10, 2026, 2:03 PM EST
Completed Phase 3 Interventional Results available

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

NCT01183013
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Pioglitazone 15 mg, Pioglitazone 45 mg, Pioglitazone 30 mg, Linagliptin 5mg / Pioglitazone 45 mg FDC, Linagliptin 5mg / Pioglitazone 30 mg FDC, Linagliptin 5mg, Linagliptin 5mg / Pioglitazone 15 mg FDC
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
936 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
74
States / cities
Birmingham, Alabama • Montgomery, Alabama • Muscle Shoals, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Nov 10, 2026, 2:03 PM EST